Receptor News and Research

RSS

Researchers show how ER-positive breast cancer tumors become resistant to tamoxifen

Researchers have shown how estrogen receptor-positive breast cancer tumors become resistant to tamoxifen, the only approved hormonal therapy for premenopausal patients with this type of breast cancer.

14 Nov 2011

Scientists suppress NCoR1 protein and create mighty mice

A team of researchers at EPFL, the University of Lausanne and the Salk Institute created super strong, marathon mice and nematodes by reducing the function of a natural inhibitor, suggesting treatments for age-related or genetically caused muscle degeneration are within reach.

11 Nov 2011

NCCN ORP to evaluate clinical effectiveness of Boehringer Ingelheim's Afatinib in solid tumors

The National Comprehensive Cancer Network Oncology Research Program (ORP) has been awarded a $2 million grant from Boehringer Ingelheim Pharmaceuticals, Inc. to develop a program to scientifically evaluate and define the clinical effectiveness of Afatinib (BIBW 2992) in solid tumors, including breast, head and neck, and non-small cell lung (NSCL) cancers.

11 Nov 2011

British researchers discover receptor necessary for malaria parasite to invade red blood cells, offering new vaccine hope

Researchers from the Wellcome Trust Sanger Institute in the U.K. have "made a critical discovery about the way the most deadly species of malaria parasite invades human red blood cells," Reuters reports.

11 Nov 2011

New unsuspected role for nuclear receptor corepressor protein

By knocking out a key regulatory protein, scientists at the University of California, San Diego School of Medicine and the Ecole Polytechnique Federale de Lausanne (EPFL) in Switzerland dramatically boosted insulin sensitivity in lab mice, an achievement that opens a new door for drug development and the treatment of diabetes.

11 Nov 2011

Universally effective malaria vaccine on the horizon

Scientists are excited with a new breakthrough in development of an effective vaccine against malaria. The latest study finds how malaria acts and how the vaccine would be able to protect individuals from malaria.

10 Nov 2011

Accumetrics VerifyNow test shows patients with high PRU exhibit higher stent thrombosis

Accumetrics, Inc., developer of the VerifyNow System, the first rapid and easy-to-use point-of-care system for measuring platelet reactivity to multiple antiplatelet agents, today announced that patients with high platelet reactivity, i.e. high PRU values as measured by the Accumetrics VerifyNow P2Y12 Test, exhibited an approximately four times higher rate of stent thrombosis than patients without high platelet reactivity, as seen in the ADAPT-DES registry.

10 Nov 2011

New genetic approach to treat fibrodysplasia ossificans progressiva

Scientists at Penn's Perelman School of Medicine Center for Research in FOP and Related Disorders have developed a new genetic approach to specifically block the damaged copy of the gene for a rare bone disease, while leaving the normal copy untouched.

9 Nov 2011

Idera third quarter net loss increases to $5.5 million

Idera Pharmaceuticals, Inc. today reported financial results for the third quarter ended September 30, 2011. Idera is a biotechnology company engaged in the discovery and development of DNA- and RNA-based drug candidates targeted to Toll-like receptors (TLRs).

9 Nov 2011

Celgene to initiate apremilast Phase III placebo-controlled trial for ankylosing spondylitis

Celgene International Sàrl, a subsidiary of Celgene Corporation, today announced data from a Phase II study of apremilast, its investigational oral immunomodulatory compound, in patients with ankylosing spondylitis (AS) were presented at the American College of Rheumatology Scientific Meeting in Chicago, IL.

9 Nov 2011

UCSB researchers study how genotypes can express themselves differently as a function of culture

Two psychologists at UC Santa Barbara have provided a new twist on the old adage that people are products of both nature and nurture, in introducing a framework for understanding how these influences interact.

9 Nov 2011

Ligand third quarter total revenues decrease to $5.7 million

Ligand Pharmaceuticals Incorporated today announced financial results for the three and nine months ended September 30, 2011 and provided a business update.

9 Nov 2011

Amylin and Lilly terminate exenatide alliance, resolve litigation

Amylin Pharmaceuticals, Inc. and Eli Lilly and Company today announced an agreement to terminate their alliance for exenatide and resolve the outstanding litigation between the companies.

9 Nov 2011

Interim data from Cytheris CYT107 Phase I/IIa combination study on HCV

Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced that data from an interim analysis of its ECLIPSE 2 Phase I/IIa study indicate that treatment with four weeks of the Company's investigative immune-modulator, recombinant human Interleukin-7, added to peginterferon and ribavirin in genotype 1 and 4 treatment experienced patients defined as nonresponders to SOC, induces a broad immune response associated with HCV viral clearance in genotype 1 and 4 treatment experienced patients defined as nonresponders to SOC.

9 Nov 2011

Access partners to exploit CobaCyte and CobOral technology for targeted RNAi therapeutic delivery

ACCESS PHARMACEUTICALS, INC., a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, announced it has entered into an agreement with a major player in RNAi industry to exploit its CobaCyte and CobOral technology for the targeted delivery of RNAi therapeutics.

9 Nov 2011

Positive results from ChemoCentryx CCX354 Phase II study on RA

ChemoCentryx, Inc., today announced that it reported positive Phase II results for CCX354 at the Annual Meeting of the American College of Rheumatology.

9 Nov 2011

Lapatinib drug could also treat head and neck cancers

A class of drugs used to treat breast cancers which overproduce a protein called HER2 could also treat other types of cancer - particularly head and neck cancers, according to research presented at the National Cancer Research Institute (NCRI) Cancer Conference in Liverpool this week.

8 Nov 2011

Older women do not benefit from improvements in breast cancer treatments

The survival rates for older women with breast cancer lag behind younger women diagnosed with the disease, indicating that the elder population may be missing out on improvements in treatment and detection, according to new research from the University of Texas MD Anderson Cancer Center.

8 Nov 2011

TWIST protein plays a major role in controlling estrogen resistance in breast cancer

In dozens of experiments in mice and in human cancer cells, a team of Johns Hopkins scientists has closely tied production of a cancer-causing protein called TWIST to the development of estrogen resistance in women with breast cancer.

8 Nov 2011

Bristol-Myers Squibb receives FDA approval for Erbitux to treat head and neck cancer

The U.S. Food and Drug Administration today approved Erbitux (cetuximab) for use with chemotherapy to treat patients with late-stage (metastatic) head and neck cancer.

8 Nov 2011

Receptor News and Research

Researchers show how ER-positive breast cancer tumors become resistant to tamoxifen

Scientists suppress NCoR1 protein and create mighty mice

NCCN ORP to evaluate clinical effectiveness of Boehringer Ingelheim's Afatinib in solid tumors

British researchers discover receptor necessary for malaria parasite to invade red blood cells, offering new vaccine hope

New unsuspected role for nuclear receptor corepressor protein

Universally effective malaria vaccine on the horizon

Accumetrics VerifyNow test shows patients with high PRU exhibit higher stent thrombosis

New genetic approach to treat fibrodysplasia ossificans progressiva

Idera third quarter net loss increases to $5.5 million

Celgene to initiate apremilast Phase III placebo-controlled trial for ankylosing spondylitis

UCSB researchers study how genotypes can express themselves differently as a function of culture

Ligand third quarter total revenues decrease to $5.7 million

Amylin and Lilly terminate exenatide alliance, resolve litigation

Interim data from Cytheris CYT107 Phase I/IIa combination study on HCV

Access partners to exploit CobaCyte and CobOral technology for targeted RNAi therapeutic delivery

Positive results from ChemoCentryx CCX354 Phase II study on RA

Lapatinib drug could also treat head and neck cancers

Older women do not benefit from improvements in breast cancer treatments

TWIST protein plays a major role in controlling estrogen resistance in breast cancer

Bristol-Myers Squibb receives FDA approval for Erbitux to treat head and neck cancer

Industry Focus eBook - Forensics & toxicology (2nd edition) eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News